|
Mr. Cunningham possesses an impressive breadth of expertise which spans nearly every aspect of the biotechnology and biopharmaceutical industries -- from legal practice to operations. Prior to his current position as CEO of Trellis Bioscience, Mr. Cunningham was Of Counsel to Cooley Godward Kronish LLP. He rejoined the firm in 2003, having previously served as a partner and the head of the firm's life sciences practice from 1989-1998. During the time between his tenures at Cooley Godward Kronish LLP, he held the positions of president and chief operating officer of Rigel Pharmaceuticals, Inc., where he played a critical role in strategically growing the company into a late-stage developer of innovative pharmaceutical products. His numerous contributions to Rigel Pharmaceuticals included providing key oversight for the company's successful initial public offering in 2000. From 1982-1988, he was a member of Genentech's senior management team during a period of rapid growth for the company. Serving as Genentech's vice president, secretary and general counsel, Mr. Cunningham was responsible for completing a number of significant corporate partnering transactions with major pharmaceutical companies around the world, as well as overseeing numerous innovative financial transactions.Mr. Cunningham also presently serves as chief executive officer of DaoGen, Inc. and Clerigen, Inc., both early stage biopharmaceutical companies, and is a director of Synarc, Inc., a private, imaging-based clinical research organization.He received his J.D. in 1970 from Washington University in St. Louis and is a member of the bar in California, New York and Missouri, as well as the American Law Institute | 